Gilead Sciences, Inc has announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre─exposure prophylaxis (PrEP) use across all 50 US states and the District of Columbia.